FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W56514888> ?p ?o ?g. }

• W56514888 endingPage "163" @default.
• W56514888 startingPage "163" @default.
• W56514888 abstract "Dear Sir: We wish to comment on feline visual changes associated with enrofloxacin, following publication of the article by Abrams-Ogg et al (Can Vet J 2002;43:53–54). These changes occur rarely — 1 report per 122 414 treated cats — even though enrofloxacin has an extensive history of use when compared with other veterinary fluoroquinolones. The dosage of enrofloxacin prescribed for the cat described by Abrams-Ogg et al was well in excess of the manufacturer's recommended dosage. In our recent year-2000 feline safety study, early results indicated that adverse effects on the visual system are seen at high doses of enrofloxacin. Bayer Inc. immediately and proactively communicated new dosage information to veterinarians. The revised dosage for cats was not to exceed 5 mg/kg bodyweight (BW) once daily. Upon completion of the study, a second letter was sent to veterinarians with updates on the new label and dosage, as approved by the Veterinary Drugs Directorate (previously Bureau of Veterinary Drugs). The current label dosage for cats is 5 mg/kg once daily for up to 30 days. The flexible regimen of 5 to 20 mg/kg BW once daily for up to 30 d remains unchanged for dogs.The historical case described by Abrams-Ogg et al had a variety of clinical challenges, including hepatopathy and pyelonephritis, and a history of visual changes prior to enrofloxacin use. The plasma levels of enrofloxacin may have been markedly elevated because of the combination of drug overdose and compromised clearance. In some other reported cases, concurrent clinical conditions may have contributed to the visual changes. Therefore, it is important to fully investigate all cases of visual changes suspected of being associated with enrofloxacin before reaching a conclusion. All adverse cases suspected of being associated with the use of enrofloxacin that are reported to Bayer Inc.'s technical veterinary services are thoroughly investigated with a panel of tests, including ocular examination and electroretinographic recordings by a board certified veterinary ophthalmologist. As an ethical and responsible company committed to animal health, Bayer Inc. feels strongly that the collection of such data is paramount in helping to elucidate the true cause of the clinical signs. This workup is important support for practitioners faced with a suspect adverse event.This investigative support, along with Bayer Inc.'s cooperative initiatives with the veterinary ophthalmology community, its close correspondence with the Veterinary Drugs Directorate, and its timely communication plan (1,2), should give practitioners the confidence to use Baytril, according to label directions, safely and effectively." @default.
• W56514888 created "2016-06-24" @default.
• W56514888 creator A5035794371 @default.
• W56514888 date "2002-03-01" @default.
• W56514888 modified "2023-09-23" @default.
• W56514888 title "Feline visual changes associated with enrofloxacin." @default.
• W56514888 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/339182" @default.
• W56514888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11901587" @default.
• W56514888 hasPublicationYear "2002" @default.
• W56514888 type Work @default.
• W56514888 sameAs 56514888 @default.
• W56514888 citedByCount "2" @default.
• W56514888 crossrefType "posted-content" @default.
• W56514888 hasAuthorship W56514888A5035794371 @default.
• W56514888 hasConcept C126322002 @default.
• W56514888 hasConcept C185592680 @default.
• W56514888 hasConcept C197934379 @default.
• W56514888 hasConcept C2778512257 @default.
• W56514888 hasConcept C2779904517 @default.
• W56514888 hasConcept C2779906673 @default.
• W56514888 hasConcept C2781413609 @default.
• W56514888 hasConcept C2909766688 @default.
• W56514888 hasConcept C2994320889 @default.
• W56514888 hasConcept C42972112 @default.
• W56514888 hasConcept C43617362 @default.
• W56514888 hasConcept C501593827 @default.
• W56514888 hasConcept C71924100 @default.
• W56514888 hasConcept C86803240 @default.
• W56514888 hasConcept C89423630 @default.
• W56514888 hasConcept C98274493 @default.
• W56514888 hasConceptScore W56514888C126322002 @default.
• W56514888 hasConceptScore W56514888C185592680 @default.
• W56514888 hasConceptScore W56514888C197934379 @default.
• W56514888 hasConceptScore W56514888C2778512257 @default.
• W56514888 hasConceptScore W56514888C2779904517 @default.
• W56514888 hasConceptScore W56514888C2779906673 @default.
• W56514888 hasConceptScore W56514888C2781413609 @default.
• W56514888 hasConceptScore W56514888C2909766688 @default.
• W56514888 hasConceptScore W56514888C2994320889 @default.
• W56514888 hasConceptScore W56514888C42972112 @default.
• W56514888 hasConceptScore W56514888C43617362 @default.
• W56514888 hasConceptScore W56514888C501593827 @default.
• W56514888 hasConceptScore W56514888C71924100 @default.
• W56514888 hasConceptScore W56514888C86803240 @default.
• W56514888 hasConceptScore W56514888C89423630 @default.
• W56514888 hasConceptScore W56514888C98274493 @default.
• W56514888 hasIssue "3" @default.
• W56514888 hasLocation W565148881 @default.
• W56514888 hasOpenAccess W56514888 @default.
• W56514888 hasPrimaryLocation W565148881 @default.
• W56514888 hasRelatedWork W1488775496 @default.
• W56514888 hasRelatedWork W2053515200 @default.
• W56514888 hasRelatedWork W2091785451 @default.
• W56514888 hasRelatedWork W2285753024 @default.
• W56514888 hasRelatedWork W2737648111 @default.
• W56514888 hasRelatedWork W2755277852 @default.
• W56514888 hasRelatedWork W2911306799 @default.
• W56514888 hasRelatedWork W4212926521 @default.
• W56514888 hasRelatedWork W56514888 @default.
• W56514888 hasRelatedWork W2307282845 @default.
• W56514888 hasVolume "43" @default.
• W56514888 isParatext "false" @default.
• W56514888 isRetracted "false" @default.
• W56514888 magId "56514888" @default.
• W56514888 workType "article" @default.